CoChat

Striatal dopamine release in schizophrenia comorbid with substance dependence

Open access
Thompson, J L, Urban, N, Slifstein, M, Xu, X, Kegeles, L S, Girgis, R R, Beckerman, Y, Harkavy-Friedman, J M, Gil, R, Abi-Dargham, A · 2013 · Molecular Psychiatry
Cited by 106

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Dopamine (DA) has a role in the pathophysiology of schizophrenia and addiction. Imaging studies have indicated that striatal DA release is increased in schizophrenia, predominantly in the precommissural caudate (preDCA), and blunted in addiction, mostly in the ventral striatum (VST). Therefore, we aimed to measure striatal DA release in patients with comorbid schizophrenia and substance dependence. We used [11C]raclopride positron emission tomography and an amphetamine challenge to measure baseline DA D2-receptor availability (BPND) and its percent change post-amphetamine (ΔBPND, to index amphetamine-induced DA release) in striatal subregions in 11 unmedicated, drug-free patients with both schizophrenia and substance dependence, and 15 healthy controls. There were no significant group differences in baseline BPND. Linear mixed modeling using ΔBPND as the dependent variable and striatal region of interest as a repeated measure indicated a significant main effect of diagnosis, F(1, 24)=8.38, P=0.008, with significantly smaller ΔBPND in patients in all striatal subregions (all P⩽0.04) except VST. Among patients, change in positive symptoms after amphetamine was significantly associated with ΔBPND in the preDCA (rs=0.69, P=0.03) and VST (rs=0.64, P=0.05). In conclusion, patients with comorbid schizophrenia and substance dependence showed significant blunting of striatal DA release, in contrast to what has been found in schizophrenia without substance dependence. Despite this blunting, DA release was associated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia. This is the first description of a group of patients with schizophrenia who display low presynaptic DA release, yet show a psychotic reaction to increases in D2 stimulation, suggesting abnormal postsynaptic D2 function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2012.109

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 28

  1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761–767. · DOI · Paper page
  2. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R . Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46: 56–72. · DOI · Paper page
  3. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006; 57: 1110–1116. · DOI
  4. Swendsen J, Ben-Zeev D, Granholm E . Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry 2011; 168: 202–209. · DOI · Paper page
  5. Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174: 150–153. · DOI · Paper page
  6. Van Mastrigt S, Addington J, Addington D . Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69–72. · DOI · Paper page
  7. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515–520. · DOI · Paper page
  8. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141–148. · DOI · Paper page
  9. Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, van Os J . Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr Scand 1999; 100: 389–395. · DOI · Paper page
  10. Schiffer B, Muller BW, Scherbaum N, Forsting M, Wiltfang J, Leygraf N et al. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 2010; 133: 3093–3103. · DOI
  11. Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB et al. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci 2010; 35: 95–104. · doi:10.1503/jpn.090049 · Paper page
  12. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV . Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry 2003; 60: 245–252. · DOI · Paper page
  13. Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P . Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 2009; 259: 28–36. · DOI
  14. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R . Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry 2006; 163: 689–696. · DOI · Paper page
  15. Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch Gen Psychiatry 1994; 51: 849–859. · DOI · Paper page
  16. First MB, Spitzer RL, Gibbon M, Williams JBW . Structured Clinical Interview for DSM-IV Axis I Disorders - Non-Patient Edition. New York Biometrics Research: New York State Psychiatric Institute, New York, NY, USA, 1996.
  17. Hollingshead AB . Four Factor Index of Social Status, Working paper Connecticut, 1975 (Unpublished Working Paper, Department of Sociology, Yale University, New Haven, CT, USA).
  18. Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276. · DOI · Paper page
  19. Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE . Measurement of dopamine release with continuous infusion of [11C]raclopride: Optimization and signal-to-noise considerations. J Nucl Med 2000; 41: 522–530.
  20. van Kammen DP, Murphy DL . Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 1975; 44: 215–224. · DOI · Paper page
  21. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36: 1182–1190.
  22. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 2009; 166: 1170–1177. · DOI · Paper page
  23. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al. Dopamine release in chronic cannabis users: A [(11)C]raclopride positron emission tomography study. Biol Psychiatry 2012; 71: 677–683. · DOI · Paper page
  24. Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008; 165: 507–514. · DOI · Paper page
  25. Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA . Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse 2009; 63: 681–689. · DOI · Paper page
  26. Michaelides M, Thanos PK, Kim R, Cho J, Ananth M, Wang GJ et al. PET imaging predicts future body weight and cocaine preference. Neuroimage 2012; 59: 1508–1513. · DOI
  27. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies. Arch Gen Psychiatry 2012: doi:10.1001/archgenpsychiatry.2012.1169. · DOI · Paper page
  28. Schubert KO, Focking M, Prehn JH, Cotter DR . Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 2011; 0: 1–13.

Cited by

Metadata

Authors
Thompson, J. L., Urban, N., Slifstein, M., Xu, X., Kegeles, L. S., Girgis, R. R., Beckerman, Y., Harkavy-Friedman, J. M., Gil, R., & Abi-Dargham, A.
Venue
Molecular Psychiatry
Published
2012-08-07
Volume
18
Issue
8
Pages
909-915
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2003077005
Cited by
106
References
15
FWCI
6.35
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.